Biosimilars

TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians

Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.